{"id":47111,"date":"2014-06-11T17:00:29","date_gmt":"2014-06-11T21:00:29","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=47111"},"modified":"2014-06-11T17:00:03","modified_gmt":"2014-06-11T21:00:03","slug":"tomorrow-2","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2014\/06\/11\/tomorrow-2\/","title":{"rendered":"tomorrow&#8230;"},"content":{"rendered":"\n<ul>\n<ol>\n<div align=\"justify\" class=\"small\"><em>Tomorrow, and tomorrow, and tomorrow,<br \/>   Creeps in this petty pace from day to day,<br \/>   To the last syllable of recorded time;<br \/>   And all our yesterdays have lighted fools<br \/>   The way to dusty death&#8230;<\/em><\/div>\n<div align=\"center\" class=\"small\"><em>Macbeth by Wiliam Shakespeare<\/em><\/div>\n<\/ol>\n<\/ul>\n<blockquote>\n<div align=\"center\" class=\"big\"><a href=\"http:\/\/www.euractiv.com\/sections\/health-consumers\/growing-concerns-over-medicines-agencys-proposed-rules-transparency-302733\" target=\"_blank\">Growing concerns over medicines agency&#8217;s proposed rules for transparency<\/a><\/div>\n<div align=\"center\" class=\"big\"><strong><font color=\"#200020\">EurActiv <\/font><\/strong><\/div>\n<div align=\"center\" class=\"middle\">by Henriette Jacobsen<\/div>\n<div align=\"center\" class=\"small\">June 11, 2014<\/div>\n<p align=\"justify\">A  growing number of health and consumer advocacy organisations are urging  the European Medicines Agency (EMA) to rethink its proposals to  restrict the viewing of clinical trial results ahead of <strong><font color=\"#660033\">a board meeting  Thursday [12 June]<\/font><\/strong>. The EMA has proposed that future access to clinical trials results  should be available &lsquo;on screen only&rsquo;. This version would exclude the  possibility of individuals being able to print, distribute, or transfer  the information, making scientific analysis of clinical study data  &quot;highly problematic&quot; according to critics.<\/p>\n<p align=\"justify\">The results of all future clinical trials in Europe could eventually  be made publicly accessible online because, on 2 April this year, the  European Parliament voted in&nbsp;favour&nbsp;of a legislative proposal to make  clinical trial data public. Last month, the European Ombudsman, Emily O&#8217;Reilly, wrote an open  letter to the EMA&#8217;s executive director Guido Rasi, expressing concern  that there has been &quot;a significant change in EMA&#8217;s policy, which could  undermine the fundamental right of public access to documents  established by EU law.&quot;<\/p>\n<p><strong>{Read:<\/strong> <a target=\"_blank\" href=\"http:\/\/www.euractiv.com\/sections\/health-consumers\/eu-ombudsman-worried-over-lack-transparency-medicines-agency-302244\">EU Ombudsman worried over lack of transparency at medicines agency}<\/a><\/p>\n<p align=\"justify\">Likewise, Glenis Willmott, the previous rapporteur on the EU&#8217;s  Clinical Trials Regulation, sent a letter to Rasi, saying she is very  concerned about the EMA&#8217;s direction of the draft policy. &quot;As has already been pointed out by numerous academic researchers,  transparency campaigners, health and consumer organisations, as well as  the European Ombudsman, the draft policy represents a step back from  (the) EMA&#8217;s previous position and a step away from the provisions of the  newly agreed Clinical Trials Regulation,&quot; the British MEP wrote.<\/p>\n<p align=\"justify\">Ahead of the EMA management board meeting Thursday, comprised mostly  of representatives from EU member state health authorities, the European  Consumer Organisation [BEUC] also encouraged the board to veto the new  proposals. Ilaria Passarani, senior Health Policy Officer at BEUC, stated that <strong><font color=\"#660033\"> public health interests should outweigh any consideration of commercial  confidentiality.<\/font><\/strong> &quot;EMA&rsquo;s U-turn from earlier promises for more transparency is  unacceptable. Should the plans go through as they are, consumers and  researchers would have only partial access to trial reports, in  &#8216;screen-only&#8217; mode and with no possibility to save, print or transfer  the information,&quot; Passarani said. &ldquo;EMA is about to set an important  precedent which could inspire regulators of medicines in the EU and  beyond, provided transparency is put back at the heart of its new  policy. We hope EMA will live up to expectations,&rdquo; she added.<\/p>\n<div align=\"justify\">Dr Roberto Frontini, president of the European Association of  Hospital Pharmacists [EAHP] stated that transparency in the reporting of  clinical trial results matters.&quot;It matters because it is important in avoiding duplicated effort. It  matters because patients participating do so on the basis that they are  assisting wider scientific understanding of medical issues. It matters  because independent secondary scrutiny of clinical trial results  frequently yields new insights,&quot; Frontini stated.<\/div>\n<\/blockquote>\n<div align=\"justify\" class=\"small\">The European Medicines Agency has a chance to do something decent tomorrow &#8211; not <em>back down<\/em>, but <em>back up<\/em> and think about what they are doing. They can set an example for the world by continuing on their original path to genuine Data Transparency, or they can fall prey to the same kind of strangulating commercial influences that have afflicted the US.<\/div>\n<div align=\"center\" class=\"small\"><img decoding=\"async\" height=\"180\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/fingers-crossed.gif\" \/>&nbsp;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tomorrow, and tomorrow, and tomorrow, Creeps in this petty pace from day to day, To the last syllable of recorded time; And all our yesterdays have lighted fools The way to dusty death&#8230; Macbeth by Wiliam Shakespeare Growing concerns over medicines agency&#8217;s proposed rules for transparency EurActiv by Henriette Jacobsen June 11, 2014 A growing [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-47111","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/47111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=47111"}],"version-history":[{"count":14,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/47111\/revisions"}],"predecessor-version":[{"id":47133,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/47111\/revisions\/47133"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=47111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=47111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=47111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}